A panel of the FDA has approved a new drug from Eli Lilly that could slow the cognitive decline due to Alzheimer’s.This could set the stage for the treatment to be approved for people with mild dementia caused by the disease.
The panel agreed that the drug, known as Donanemab, has been shown to slow the progression by removing plaque buildups in the brain. Removing the plaque seems to slow down the brain changes that seem to happen with Alzheimer’s. There is currently no cure and no drug to prevent the disease, by Donanemab and another drug Leqembi have been shown to slow it’s progression. Legembi is already on the market. Eli Lilly says their new drug shows highly meaningful results, with a 37% lower risk of progression of the disease.
